152 related articles for article (PubMed ID: 36928565)
1. Infliximab response associates with radiologic findings in bio-naïve Crohn's disease.
Yueying C; Jing F; Qi F; Jun S
Eur Radiol; 2023 Aug; 33(8):5247-5257. PubMed ID: 36928565
[TBL] [Abstract][Full Text] [Related]
2. Are Radiomic Spleen Features Useful for Assessing the Response to Infliximab in Patients With Crohn's Disease? A Multicenter Study.
Tang CT; Yin F; Yin Y; Liu Z; Long S; Zeng CY; Chen Y; Chen YX
Clin Transl Gastroenterol; 2024 May; 15(5):e00693. PubMed ID: 38407213
[TBL] [Abstract][Full Text] [Related]
3. Bioelectrical impedance analysis-based nomogram construction for predicting secondary loss of response to infliximab in bio-naïve Crohn's disease patients.
Yueying C; Jing F; Tian Y; Yuqi Q; Jun S
Biomed Pharmacother; 2021 Oct; 142():112076. PubMed ID: 34449314
[TBL] [Abstract][Full Text] [Related]
4. A Matrix-based Model Predicts Primary Response to Infliximab in Crohn's Disease.
Billiet T; Papamichael K; de Bruyn M; Verstockt B; Cleynen I; Princen F; Singh S; Ferrante M; Van Assche G; Vermeire S
J Crohns Colitis; 2015 Dec; 9(12):1120-6. PubMed ID: 26351386
[TBL] [Abstract][Full Text] [Related]
5. Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn's disease under infliximab therapy.
Cao WT; Huang R; Liu S; Fan YH; Xu MS; Xu Y; Ni H
World J Gastroenterol; 2022 Jun; 28(23):2582-2596. PubMed ID: 35949356
[TBL] [Abstract][Full Text] [Related]
6. CT enterography-based radiomics combined with body composition to predict infliximab treatment failure in Crohn's disease.
Song F; Ma M; Zeng S; Shao F; Huang W; Feng Z; Rong P
Radiol Med; 2024 Feb; 129(2):175-187. PubMed ID: 37982937
[TBL] [Abstract][Full Text] [Related]
7. Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease.
Beltrán B; Iborra M; Sáez-González E; Marqués-Miñana MR; Moret I; Cerrillo E; Tortosa L; Bastida G; Hinojosa J; Poveda-Andrés JL; Nos P
Dig Dis; 2019; 37(2):108-115. PubMed ID: 30149385
[TBL] [Abstract][Full Text] [Related]
8. Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease.
Benmassaoud A; Al-Taweel T; Sasson MS; Moza D; Strohl M; Kopylov U; Paradis-Surprenant L; Almaimani M; Bitton A; Afif W; Lakatos PL; Bessissow T
Dig Dis Sci; 2018 May; 63(5):1302-1310. PubMed ID: 29243105
[TBL] [Abstract][Full Text] [Related]
9. A novel clinical radiomics nomogram at baseline to predict mucosal healing in Crohn's disease patients treated with infliximab.
Zhu C; Hu J; Wang X; Li C; Gao Y; Li J; Ge Y; Wu X
Eur Radiol; 2022 Oct; 32(10):6628-6636. PubMed ID: 35857074
[TBL] [Abstract][Full Text] [Related]
10. Infliximab trough levels are associated with endoscopic healing but not with transmural healing at one year treatment with infliximab in pediatric patients with Crohn's disease.
Choi SY; Kwon Y; Choi S; Lee SM; Choe BH; Kang B
Front Immunol; 2023; 14():1192827. PubMed ID: 37426637
[TBL] [Abstract][Full Text] [Related]
11. [Association between drug trough concentration and disease outcome before infliximab maintenance treatment in children with Crohn's disease].
Deng X; Yu Y; Wang XQ; Li J; Xu X; Xu CD; Xiao Y
Zhongguo Dang Dai Er Ke Za Zhi; 2022 Nov; 24(11):1246-1251. PubMed ID: 36398551
[TBL] [Abstract][Full Text] [Related]
12. A Novel Radiomics Nomogram for the Prediction of Secondary Loss of Response to Infliximab in Crohn's Disease.
Chen Y; Li H; Feng J; Suo S; Feng Q; Shen J
J Inflamm Res; 2021; 14():2731-2740. PubMed ID: 34194236
[TBL] [Abstract][Full Text] [Related]
13. Early serum infliximab trough level and mucosal healing could be predictors for one-year outcome after initiating therapy in Crohn's disease.
Tang J; Yang Q; Huang Z; Guo H; Chao K; Hu P; Gao X
Scand J Gastroenterol; 2020 Sep; 55(9):1035-1040. PubMed ID: 32819192
[TBL] [Abstract][Full Text] [Related]
14. Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohn's disease.
Gagniere C; Beaugerie L; Pariente B; Seksik P; Amiot A; Abitbol V; Allez M; Cosnes J; Sokol H
J Crohns Colitis; 2015 Apr; 9(4):349-55. PubMed ID: 25547977
[TBL] [Abstract][Full Text] [Related]
15. Infliximab Exposure Associates With Radiologic Evidence of Healing in Patients With Crohn's Disease.
Bossuyt P; Dreesen E; Rimola J; Devuysere S; De Bruecker Y; Vanslembrouck R; Laurent V; Zappa M; Savoye-Collet C; Pariente B; Filippi J; Baert F; D'Haens G; Laharie D; Peyrin-Biroulet L; Vermeire S;
Clin Gastroenterol Hepatol; 2021 May; 19(5):947-954.e2. PubMed ID: 32360982
[TBL] [Abstract][Full Text] [Related]
16. A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-naïve and Non-naïve Patients With Crohn's Disease: Real-Life Data From the Sicilian Network for Inflammatory Bowel Disease.
Macaluso FS; Fries W; Privitera AC; Cappello M; Siringo S; Inserra G; Magnano A; Di Mitri R; Mocciaro F; Belluardo N; Scarpulla G; Magrì G; Trovatello A; Carroccio A; Genova S; Bertolami C; Vassallo R; Romano C; Citrano M; Accomando S; Ventimiglia M; Renna S; Orlando R; Rizzuto G; Porcari S; Ferracane C; Cottone M; Orlando A;
J Crohns Colitis; 2019 Feb; 13(2):209-217. PubMed ID: 30295785
[TBL] [Abstract][Full Text] [Related]
17. CT-based pancreatic radiomics predicts secondary loss of response to infliximab in biologically naïve patients with Crohn's disease.
Yang T; Feng J; Yao R; Feng Q; Shen J
Insights Imaging; 2024 Mar; 15(1):69. PubMed ID: 38472447
[TBL] [Abstract][Full Text] [Related]
18. Development of a clinical model to predict secondary non-response of infliximab treatment in Crohn's disease.
Xu L; Shen J; Zheng Q
Int J Colorectal Dis; 2020 Nov; 35(11):2019-2026. PubMed ID: 32577870
[TBL] [Abstract][Full Text] [Related]
19. A random forest model predicts responses to infliximab in Crohn's disease based on clinical and serological parameters.
Li Y; Pan J; Zhou N; Fu D; Lian G; Yi J; Peng Y; Liu X
Scand J Gastroenterol; 2021 Sep; 56(9):1030-1039. PubMed ID: 34304688
[TBL] [Abstract][Full Text] [Related]
20. Factors predicting the therapeutic response to infliximab during maintenance therapy in Japanese patients with Crohn's disease.
Matsuoka K; Hamada S; Shimizu M; Nanki K; Mizuno S; Kiyohara H; Arai M; Sugimoto S; Iwao Y; Ogata H; Hisamatsu T; Naganuma M; Kanai T; Mochizuki M; Hashiguchi M
PLoS One; 2018; 13(10):e0204632. PubMed ID: 30286108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
